Search results
Results from the WOW.Com Content Network
Dapagliflozin, sold under the brand names Farxiga (US) and Forxiga (EU) among others, is a medication used to treat type 2 diabetes. [ 6 ] [ 7 ] [ 10 ] It is also used to treat adults with heart failure and chronic kidney disease .
AstraZeneca’s Farxiga drug, which treats chronic kidney disease, heart failure and Type 2 diabetes, was among the 10 medications selected last year for the initial round of price negotiations ...
These programs were known as "Medicare+Choice" or "Part C" plans. Pursuant to the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, the compensation and business practices for insurers that offer these plans changed, and "Medicare+Choice" plans became known as "Medicare Advantage" (MA) plans.
The 71st Edition, published in 2017, was the final hardcover edition, weighed in at 4.6 pounds (2.1 kg) and contained information on over 1,000 drugs. [1] Since then, the PDR has been available online for free. The Physicians' Desk Reference was first published in 1947 by Medical Economics Inc., a magazine publisher founded by Lansing Chapman. [2]
Farxiga (dapagliflozin) is a "sodium-glucose co-transporter 2 inhibitor", or SGLT2 inhibitor for short, in tablet form which helps to What Does This New Diabetes Drug Mean for AstraZeneca and ...
When used appropriately, formularies can help manage drug costs imposed on the insurance policy. [7] However, for drugs that are not on formulary, patients must pay a larger percentage of the cost of the drug, sometimes 100%. Formularies vary between drug plans and differ in the breadth of drugs covered and costs of co-pay and premiums.
An online version is available, with all drug listings available to view for free. Concise drug monographs form the core of MIMS; these include safety information, details of the active ingredient, presentation, price, indication, dosage and manufacturer. In addition, the book includes drug comparison tables, and summaries of clinical guidance.
The United States Food and Drug Administration's Investigational New Drug (IND) program is the means by which a pharmaceutical company obtains permission to start human clinical trials and to ship an experimental drug across state lines (usually to clinical investigators) before a marketing application for the drug has been approved.